Hypersensitivity to daunorubicin or any other component of the product, other anthracyclines, or anthracenediones; persistent myelosuppression; presence of severe infections; severe hepatic (Child-Pugh Grade C [total score 10-15]) or renal function impairment (GFR <10 mL/min or serum creatinine >7.9 mg/dL); myocardial insufficiency; recent myocardial infarction; severe arrhythmias; previous treatments with maximum cumulative doses of daunorubicin, other anthracyclines and/or anthracenediones (see Precautions).
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Manage Account
Change Password
Sign Out
